Using immunoblotting and real-time qPCR analysis, we found that survivin expression was downregulated in the cancer cell line Cal-27 following I3M treatment, identifying survivin as a potential mediator of the anti-tumorigenic activities of I3M. Here, BIRC5 is linked to cancer.